Alle Storys
Folgen
Keine Story von MDS Nordion mehr verpassen.

MDS Nordion

MDS Nordion to Expand Facility to Meet Growing Demand for Medical Imaging Agent in Europe

Ottawa, Canada (ots/PRNewswire)

- Expanded Facility in Fleurus, Belgium to be Leading Player in
Supply  of Glucotrace(R) for Growing Market
MDS Nordion, a leading global provider of medical isotopes and
radiopharmaceuticals for molecular imaging, is investing U.S. $5.8
million  / (euro) 4.5 million to expand its production facility in
Fleurus, Belgium  to meet the growing demand for a medical imaging
agent used in cancer  diagnosis and treatment. The agent, Fluorine-18
Fludeoxyglucose or FDG, is  marketed and distributed by MDS Nordion
under the name Glucotrace(R).  Glucotrace(R) is used in a highly
sensitive medical imaging technique  called PET or Positron Emission
Tomography. As cancer rates continue to  rise in Europe, the use of
PET is increasing to diagnose cancer and monitor  patient progress
while in treatment.
Glucotrace(R) is a time-sensitive diagnostic pharmaceutical with a
limited lifespan. As a result, it is critical to have the ability to
reliably supply Glucotrace(R) to hospitals and clinical sites on
time. With  this expansion, MDS Nordion will be able to serve more
customers within  France and the Benelux Economic Union (Belgium,
Netherlands and Luxembourg).
"The new production facility will give MDS Nordion the ability to
meet  increased demand from our current customers as well as extend
our market  reach to new customers," said Steve West, President of
MDS Nordion. "We are  committed to providing a reliable supply of
Glucotrace(R) to the medical  imaging community in Europe."
Through this investment and capital upgrade, MDS Nordion will
build a  larger production centre for Glucotrace(R) within its
existing facilities  in Fleurus. The investment will also optimize
MDS Nordion's current resources  including a higher capacity
cyclotron to produce FDG.
Presently, MDS Nordion produces Glucotrace(R) as part of a joint
venture with the University of Liège (ULG) about 80 kilometres west
of  Fleurus. The new MDS Nordion facility in Fleurus, combined with
the  existing site at ULG, will greatly increase production capacity
for Europe  as well as provide the necessary manufacturing and supply
flexibility to  serve growing market demand.
First production of Glucotrace(R) from the new facility in Fleurus
is  expected to begin in mid-2008. Glucotrace(R) is approved for sale
across  Europe.
About MDS Nordion
MDS Nordion (www.mds.nordion.com) is a world leader in medical
isotopes, radiation and related technologies. It is a division of MDS
Inc.  (TSX:MDS)(NYSE:MDZ). MDS Inc. is a global life sciences company
that  provides market-leading products and services that our
customers need for  the development of drugs and diagnosis and
treatment of disease. We are a  leading global provider of
pharmaceutical contract research, medical  isotopes for molecular
imaging, radiotherapeutics, and analytical  instruments. MDS has more
than 5,600 highly skilled people in 28 countries.  Find out more at
www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.

Contact:

For further information: Media Inquiries, Olivia Nixon, MDS Nordion,
+1-(613)-592-2790 ext. 2558, +1-(613)-724-1767 (Mobile),
olivia.nixon@mdsinc.com; Investor Inquiries, Sharon Mathers,
Vice-President, Investor Relations and External Communications,
+1-(416)-675-6777 ext. 34721, sharon.mathers@mdsinc.com

Weitere Storys: MDS Nordion
Weitere Storys: MDS Nordion
  • 22.03.2006 – 14:07

    MDS Nordion Offers Advanced Cancer Therapy Systems in Europe

    Ottawa, Canada (ots/PRNewswire) - The MDS Nordion Equinox, a state-of-the-art cancer therapy system, and Avanza, a patient positioning treatment table, have received CE Mark approval and are now commercially available in Europe. The Equinox is a unique external beam therapy system providing cancer care professionals with modern functionality to maximize productivity and increase flexibility ensuring patients ...

  • 27.02.2006 – 00:03

    MDS Nordion Provides Long-term Cobalt Supply for Sterilisation Industry

    Ottawa, Canada (ots/PRNewswire) - MDS Nordion, the world's largest supplier of medical isotopes, is pleased to announce it has extended an exclusive agreement with Bruce Power to provide a reliable supply of cobalt until 2019. This partnership produces over 40% of the world's supply of cobalt, used primarily for the sterilisation of medical devices and consumer ...